Journal of Neuroimmune Pharmacology

, Volume 9, Issue 3, pp 399–412 | Cite as

An ανβ3 Integrin-Binding Peptide Ameliorates Symptoms of Chronic Progressive Experimental Autoimmune Encephalomyelitis by Alleviating Neuroinflammatory Responses in Mice

  • Fan Zhang
  • Jing Yang
  • Hong Jiang
  • Shu HanEmail author


MOG35-55 triggers chronic, progressive experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice, and the clinical course of EAE in this model is characterized by macrophage infiltration, axonal demyelination/damage, and progressive paralysis. These stages are usually associated with inflammatory responses in the central nervous system (CNS). This study was designed to investigate the effects of C16, an ανβ3 integrin-binding peptide that targets integrins involved in the transendothelial migration of extravasating inflammatory cells. C16 was applied for only 2 weeks, but the benefits of this therapy lasted at least 8 weeks. Multiple histological and immunohistochemical staining studies, western blotting, enzyme-linked immunosorbent assays, electron microscopy, and cortical somatosensory-evoked potential (c-SEP) electrophysiological tests were employed to assess the degree of inflammation, axonal loss, white matter demyelination, neuronal apoptosis, extent of gliosis, expression of pro-inflammatory cytokines, and functional recovery of differently treated EAE model mice. The results showed that C16 treatment inhibited extensive leukocyte and macrophage accumulation and infiltration, reduced the expression of pro-inflammatory cytokines (tumor necrosis factor-α and interferon-γ), and thereby attenuated and delayed the progression of EAE. Moreover, astrogliosis, demyelination, and axonal and neuronal loss were all alleviated in C16-treated EAE animals, contributing to the improvement of function. These data suggest that the C16 peptide may act as a protective agent by reducing neuroinflammatory responses and improving the microenvironment.


Multiple sclerosis Chronic, progressive experimental allergic encephalomyelitis Inflammatory cell infiltration Demyelination Neuroprotective effect 



This work was funded by the Zhejiang Provincial Natural Science Foundation of China no. R2110025 and the National Natural Science Foundation of China, project no. 81271333.

Conflict of Interest

The authors declare that they have no conflicts of interest.

Supplementary material

11481_2014_9532_MOESM1_ESM.pdf (1.7 mb)
ESM 1 (PDF 1778 kb)


  1. All AH, Walczak P, Agrawal G, Gorelik M, Lee C, Thakor NV, Bulte JW, Kerr DA (2009) Effect of MOG sensitization on somatosensory evoked potential in Lewis rats. J Neurol Sci 284:81–89PubMedCentralPubMedCrossRefGoogle Scholar
  2. Arnold SA, Hagg T (2011) Anti-inflammatory treatments during the chronic phase of spinal cord injury improve locomotor function in adult mice. J Neurotrauma 28:1995–2002PubMedCentralPubMedCrossRefGoogle Scholar
  3. Balatoni B, Storch MK, Swoboda EM, Schönborn V, Koziel A, Lambrou GN, Hiestand PC, Weissert R, Foster CA (2007) FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 74:307–316PubMedCrossRefGoogle Scholar
  4. Basso AS, Frenkel D, Quintana FJ, Costa-Pinto FA, Petrovic-Stojkovic S, Puckett L, Monsonego A, Bar-Shir A, Engel Y, Gozin M, Weiner HL (2008) Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest 118:1532–1543PubMedCentralPubMedCrossRefGoogle Scholar
  5. Berard JL, Wolak K, Fournier S, David S (2010) Characterization of relapsing-remitting and chronic forms of experimental autoimmune encephalomyelitis in C57BL/6 mice. Glia 58:434–445PubMedCrossRefGoogle Scholar
  6. Bettini M, Rosenthal K, Evavold BD (2009) Pathogenic MOG-reactive CD8+ T cells require MOG-reactive CD4+ T cells for sustained CNS inflammation during chronic EAE. J Neuroimmunol 213:60–68PubMedCentralPubMedCrossRefGoogle Scholar
  7. Brambilla R, Morton PD, Ashbaugh JJ, Karmally S, Lambertsen KL, Bethea JR (2014) Astrocytes play a key role in EAE pathophysiology by orchestrating in the CNS the inflammatory response of resident and peripheral immune cells and by suppressing remyelination. Glia 62:452–467Google Scholar
  8. Cervellini I, Ghezzi P, Mengozzi M (2013) Therapeutic efficacy of erythropoietin in experimental autoimmune encephalomyelitis in mice, a model of multiple sclerosis. Methods Mol Biol 982:163–173PubMedCrossRefGoogle Scholar
  9. Crowe MJ, Bresnahan JC, Shuman SL, Masters JN, Beattie MS (1997) Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 3:73–76PubMedCrossRefGoogle Scholar
  10. Denic A, Johnson AJ, Bieber AJ, Warrington AE, Rodriguez M, Pirko I (2011) The relevance of animal models in multiple sclerosis research. Pathophysiology 18:21–29PubMedCrossRefGoogle Scholar
  11. Devaux J, Forni C, Beeton C, Barbaria J, Béraud E, Gola M, Crest M (2003) Myelin basic protein-reactive T cells induce conduction failure in vivo but not in vitro. Neuroreport 14:317–320PubMedCrossRefGoogle Scholar
  12. Dore-Duffy P, Wencel M, Katyshev V, Cleary K (2011) Chronic mild hypoxia ameliorates chronic inflammatory activity in myelin oligodendrocyte glycoprotein (MOG) peptide induced experimental autoimmune encephalomyelitis (EAE). Adv Exp Med Biol 701:165–173PubMedCrossRefGoogle Scholar
  13. Fang M, Huang JY, Wang J, Ling SC, Rudd JA, Hu ZY, Xu LH, Yuan ZG, Han S (2011) The anti-neuroinflamatory and neurotrophic effects of combined therapy with Annexin II and Reg-2 on injured spinal cord. Neurosignals 19:16–43PubMedCrossRefGoogle Scholar
  14. Fang M, Sun Y, Hu Z, Yang J, Davies H, Wang B, Ling S, Han S (2013) C16 peptide shown to prevent leukocyte infiltration and alleviate detrimental inflammation in acute allergic encephalomyelitis model. Neuropharmacology 70C:83–99CrossRefGoogle Scholar
  15. Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis–the plaque and its pathogenesis. N Engl J Med 10:942–955CrossRefGoogle Scholar
  16. Garay L, Gonzalez Deniselle MC, Gierman L, Meyer M, Lima A, Roig P, De Nicola AF (2008) Steroid protection in the experimental autoimmune encephalomyelitis model of multiple sclerosis. Neuroimmunomodulation 15:76–83PubMedGoogle Scholar
  17. Ghezzi P, Mennini T (2001) Tumor necrosis factor and motoneuronal degeneration: an open problem. Neuroimmunomodulation 9:178–182PubMedCrossRefGoogle Scholar
  18. Han S, Arnold SA, Sithu SD, Mahoney ET, Geralds JT, Tran P, Benton RL, Maddie MA, D’Souza SE, Whittemore SR, Hagg T (2010) Rescuing vasculature with intravenous angiopoietin-1 and alpha v beta 3 integrin peptide is protective after spinal cord injury. Brain 133:1026–1042PubMedCentralPubMedCrossRefGoogle Scholar
  19. Hassen GW, Feliberti J, Kesner L, Stracher A, Mokhtarian F (2008) Prevention of axonal injury using calpain inhibitor in chronic progressive experimental autoimmune encephalomyelitis. Brain Res 1236:206–215PubMedCentralPubMedCrossRefGoogle Scholar
  20. Kanwar JR, Kanwar RK, Wang D, Krissansen GW (2000) Prevention of a chronic progressive form of experimental autoimmune encephalomyelitis by an antibody against mucosal addressin cell adhesion molecule-1, given early in the course of disease progression. Immunol Cell Biol 78:641–645PubMedCrossRefGoogle Scholar
  21. Liu XZ, Xu XM, Hu R, Du C, Zhang SX, McDonald JW, Dong HX, Wu YJ, Fan GS, Jacquin MF, Hsu CY, Choi DW (1997) Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci 17:5395–5406PubMedGoogle Scholar
  22. Ma X, Jiang Y, Wu A, Chen X, Pi R, Liu M, Liu Y (2010) Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. PLoS One 5:e13489PubMedCentralPubMedCrossRefGoogle Scholar
  23. Mangas A, Coveñas R, Bodet D, de León M, Duleu S, Geffard M (2008) Evaluation of the effects of a new drug candidate (GEMSP) in a chronic EAE model. Int J Biol Sci 4:150–160PubMedCentralPubMedCrossRefGoogle Scholar
  24. McGavern DB, Murray PD, Rivera-Quiñones C, Schmelzer JD, Low PA, Rodriguez M (2000) Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain 123:519–531PubMedCrossRefGoogle Scholar
  25. Mensah-Brown EP, Shahin A, Al Shamisi M, Lukic ML (2011) Early influx of macrophages determines susceptibility to experimental allergic encephalomyelitis in Dark Agouti (DA) rats. J Neuroimmunol 232:68–74PubMedCrossRefGoogle Scholar
  26. Merrill JE, Hanak S, Pu SF, Liang J, Dang C, Iglesias-Bregna D, Harvey B, Zhu B, McMonagle-Strucko K (2009) Teriflunomide reduces behavioral, electrophysiological, and histopathological deficits in the Dark Agouti rat model of experimental autoimmune encephalomyelitis. J Neurol 256:89–103PubMedCrossRefGoogle Scholar
  27. Murugesan N, Paul D, Lemire Y, Shrestha B, Ge S, Pachter JS (2012) Active induction of experimental autoimmune encephalomyelitis by MOG35-55 peptide immunization is associated with differential responses in separate compartments of the choroid plexus. Fluids Barriers CNS 9:15PubMedCentralPubMedCrossRefGoogle Scholar
  28. Nair A, Frederick TJ, Miller SD (2008) Astrocytes in multiple sclerosis: a product of their environment. Cell Mol Life Sci 65:2702–2720PubMedCentralPubMedCrossRefGoogle Scholar
  29. Pifarre P, Prado J, Baltrons MA, Giralt M, Gabarro P, Feinstein DL, Hidalgo J, Garcia A (2011) Sildenafil (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis. Acta Neuropathol 121:499–508PubMedCrossRefGoogle Scholar
  30. Profyris C, Cheema SS, Zang D, Azari MF, Boyle K, Petratos S (2004) Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol Dis 15:415–436PubMedCrossRefGoogle Scholar
  31. Ransohoff RM (2012) Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat Neurosci 15:1074–1077PubMedCrossRefGoogle Scholar
  32. Roy A, Liu X, Pahan K (2007) Myelin basic protein-primed T cells induce neurotrophins in glial cells via alphavbeta3 integrin. J Biol Chem 282:32222–32232PubMedCentralPubMedCrossRefGoogle Scholar
  33. Shu Y, Yang Y, Qiu W, Lu Z, Li Y, Bao J, Feng M, Hu X (2011) Neuroprotection by ulinastatin in experimental autoimmune encephalomyelitis. Neurochem Res 36:1969–1977PubMedCrossRefGoogle Scholar
  34. Slavin A, Ewing C, Liu J, Ichikawa M, Slavin J, Bernard CC (1998) Induction of a multiple sclerosis-like disease in mice with an immunodominantepitope of myelin oligodendrocyte glycoprotein. Autoimmunity 28:109–120PubMedCrossRefGoogle Scholar
  35. Soulika AM, Lee E, McCauley E, Miers L, Bannerman P, Pleasure D (2009) Initiation and progression of axonopathy in experimental autoimmune encephalomyelitis. J Neurosci 29:14965–14979PubMedCentralPubMedCrossRefGoogle Scholar
  36. Tanoue K, Yamashita S, Masuko K, Osaka J, Iai M, Yamada M (2006) Two cases of acute disseminated encephalomyelitis which occurred before the age of 24 months. No To Hattatsu 38:363–367PubMedGoogle Scholar
  37. Tegla CA, Cudrici C, Rus V, Ito T, Vlaicu S, Singh A, Rus H (2009) Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival. J Neuroimmunol 213:3–11PubMedCentralPubMedCrossRefGoogle Scholar
  38. Troncoso E, Muller D, Czellar S, Zoltan Kiss J (2000) Epicranial sensory evoked potential recordings for repeated assessment of cortical functions in mice. J Neurosci Methods 97:51–58PubMedCrossRefGoogle Scholar
  39. Troncoso E, Muller D, Korodi K, Steimer T, Welker E, Kiss JZ (2004) Recovery of evoked potentials, metabolic activity and behavior in a mouse model of somatosensory cortex lesion: role of the neural cell adhesion molecule (NCAM). Cereb Cortex 14:332–341PubMedCrossRefGoogle Scholar
  40. Voskuhl RR, Peterson RS, Song B, Ao Y, Morales LB, Tiwari-Woodruff S, Sofroniew MV (2009) Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci 29:11511–11522PubMedCentralPubMedCrossRefGoogle Scholar
  41. Warden P, Bamber NI, Li H, Esposito A, Ahmad KA, Hsu CY, Xu XM (2001) Delayed glial cell death following Wallerian degeneration in white matter tracts after spinal cord dorsal column cordotomy in adult rats. Exp Neurol 168:213–224PubMedCrossRefGoogle Scholar
  42. Weerasinghe D, McHugh KP, Ross FP, Brown EJ, Gisler RH, Imhof BA (1998) A role for the alphavbeta3 integrin in the transmigration of monocytes. J Cell Biol 142:595–607PubMedCentralPubMedCrossRefGoogle Scholar
  43. Xu J, Drew PD (2007) Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia. J Immunol 178:1904–1913PubMedCentralPubMedCrossRefGoogle Scholar
  44. Xu J, Chavis JA, Racke MK, Drew PD (2006) Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes. J Neuroimmunol 176:95–105PubMedCrossRefGoogle Scholar
  45. Yin JX, Tu JL, Lin HJ, Shi FD, Liu RL, Zhao CB, Coons SW, Kuniyoshi S, Shi J (2010) Centrally administered pertussis toxin inhibits microglia migration to the spinal cord and prevents dissemination of disease in an EAE mouse model. PLoS One 5:e12400PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Institute of Anatomy and Cell Biology, Medical CollegeZhejiang UniversityHangzhouChina
  2. 2.Department of Electrophysiology, Sir Run Run Shaw Hospital, Medical CollegeZhejiang UniversityHangzhouChina

Personalised recommendations